Table 1. Baseline epidemiological and HIV-related characteristics.
| ETR group (n = 22) | Control group (n = 21) | |
| Age, years | 47.4 (42; 51) | 46.2 (41.8; 50) |
| Gender, male (%) | 63.6 | 76.2 |
| Time since HIV diagnosis, years | 12.9 (5.9; 17.3) | 8.1 (4.2; 16.5) |
| Time on antiretroviral therapy, years | 8.3 (3.9; 12.1) | 8.1 (4.2; 16.5) |
| Time on PI, years | 3.6 (0.7; 8.2) | 5.2 (3.4; 9.6) |
| CD4 cell count/µL | 729 (512; 858) | 711 (484; 931) |
| Reason for change, n (%) | ||
| Dyslipemia | 12 (54.5) | 9 (42.9)) |
| Gastrointestinal disturbances | 3 (13.6) | 2 (9.5) |
| Posology (BID)/RTV | 7 (31.8) | 10 (47.6) |
| Use of lipid-lowering agents (LLD) n% | 4 (18.2) | 2 (9.5) |
| NNRTI, n (%) | ||
| Abacavir+Lamivudine | 8 (36.4) | 7 (33.3) |
| Tenofovir+Emtricitabine | 13 (59) | 13 (61.9) |
| Others combinations | 1 (4.6) | 1 (4.8) |
| Baseline PI, n (%) | ||
| Atazanavir/RTV (n = 23) | 11 (50.5) | 12 (57.1) |
| Lopinavir/RTV (n = 11) | 7 (31.8) | 4 (19.0) |
| Fosamprenavir/RTV (n = 6) | 3 (13.6) | 3 (14.3) |
| Saquinavir/RTV (n = 3) | 1 (4.5) | 3 (9.5) |
| Darunavir/RTV (n = 0) | 0 | 0 |
| Hepatitis C/B virus, n (%) | 3 (13.6) | 4 (19) |
Parameters are expressed as Median value (IQR 25;75) except when it was specified. HCV, hepatitis C virus; HBV, hepatitis B virus; PI, protease inhibitors; NNRTI, non-nucleoside analog reverse transcriptase inhibitor; RTV, ritonavir; BID, twice daily dosin.